Leerink Partners Reiterates Outperform Rating on Eli Lilly (LLY)

Go back to Leerink Partners Reiterates Outperform Rating on Eli Lilly (LLY)

Eli Lilly (LLY) PT Raised to $1,158 at Morgan Stanley

October 11, 2024 8:23 AM UTC

Morgan Stanley analyst Terence Flynn raised the price target on Eli Lilly (NYSE: LLY) to $1,158.00 (from $1,106.00) while maintaining a Overweight rating.... More

Eli Lilly (LLY) PT Raised to $1,033 at Truist Securities

October 10, 2024 7:05 AM UTC

(Updated - October 10, 2024 7:06 AM EDT)

Truist Securities analyst Robyn Karnauskas raised the price target on Eli Lilly (NYSE: LLY) to $1,033.00 (from $1,000.00) while maintaining a Buy rating.

The analyst commented: "Eli Lilly Model Update, PT goes to $1,033 from $1,000. We... More